Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026

Rhea-AI Summary

Nasus Pharma (NYSE: NSRX) will present data at AAAAI 2026 (Feb 27–Mar 2) on NS002, an investigational intranasal epinephrine powder. Two posters on March 1, 2026 (9:45–10:45 AM) report higher nasal deposition versus liquid spray and stability through three freeze–thaw cycles.

The presentations emphasize potential for faster epinephrine absorption and robust formulation stability for a needle‑free anaphylaxis treatment option.

News Market Reaction – NSRX

+1.02%

1 alert

+1.02% News Effect

+$488K Valuation Impact

$48M Market Cap

0.3x Rel. Volume

On the day this news was published, NSRX gained 1.02%, reflecting a mild positive market reaction. This price movement added approximately $488K to the company's valuation, bringing the market cap to $48M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

AAAAI 2026 dates: February 27 to March 2, 2026 Session time: March 1, 2026, 9:45–10:45 AM Poster ID: 592 +2 more

5 metrics

AAAAI 2026 dates February 27 to March 2, 2026 Annual Meeting where NS002 posters will be presented

Session time March 1, 2026, 9:45–10:45 AM Anaphylaxis and Venom Allergy session for both NS002 posters

Poster ID 592 Deposition comparison of nasal powder vs liquid spray

Poster ID 593 Stability of FMXIN002 intranasal epinephrine powder spray

Freeze-thaw stability cycles 3 freeze-thaw cycles FMXIN002 powder spray remained stable through these cycles

Market Reality Check

Price: $5.90 Vol: Volume 3,017 is below 20-...

low vol

$5.90 Last Close

Volume Volume 3,017 is below 20-day average 5,052 (relative volume 0.6x). low

Technical Shares at $5.90 are trading below the 200-day MA of $7.31, about 40.94% under the 52-week high and 20.41% above the 52-week low.

Peers on Argus

NSRX gained 5.36% while peers were mixed: MDCX up 7.07%, ASRT up 0.28%, but SCLX...

NSRX gained 5.36% while peers were mixed: MDCX up 7.07%, ASRT up 0.28%, but SCLX, MIRA, and INCR down between 1.69% and 3.6%, indicating a stock-specific move.

Historical Context

5 past events · Latest: Feb 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 13	Private placement closing	Negative	+5.4%	Closed $15M share and warrant financing to fund NS002 pivotal work.
Feb 10	Private placement pricing	Negative	+0.7%	Announced pricing of $15M private placement of shares and warrants.
Jan 20	Phase 2 interim data	Positive	-7.5%	Reported positive interim Phase 2 PK and safety results for NS002.
Dec 22	Shareholder letter	Positive	-6.6%	CEO outlined IPO proceeds use and NS002 clinical and corporate milestones.
Oct 8	Partnership expansion	Positive	+0.8%	Expanded Aptar agreements to support NS002 development and commercialization.

Pattern Detected

Recent history shows multiple divergences where positive NS002 or corporate updates were followed by negative price reactions.

Recent Company History

Over the last six months, NSRX has focused on advancing NS002 and corporate development. Positive interim Phase 2 data on Jan 20, 2026 and expanded Aptar agreements on Oct 8, 2025 were followed by mixed to negative price moves. Financing events in February 2026 raised $15.0M via private placements to fund pivotal NS002 work, again with varied reactions. Today’s conference-focused announcement continues the NS002 narrative without adding new clinical outcomes.

Market Pulse Summary

This announcement highlights upcoming AAAAI 2026 presentations for NS002, focusing on nasal depositi...

Analysis

This announcement highlights upcoming AAAAI 2026 presentations for NS002, focusing on nasal deposition versus liquid sprays and stability through 3 freeze-thaw cycles. It builds on earlier Phase 2 data and recent financings that support a pivotal program. Historically, NS002-related news has produced mixed price reactions, so investors may watch for full poster data, progress toward the planned pivotal study, and how these findings integrate with the broader anaphylaxis treatment landscape.

Key Terms

intranasal, epinephrine, anaphylaxis, nasal cavity, +1 more

5 terms

intranasal medical

"a clinical-stage pharmaceutical company focused on the development of innovative intranasal products"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

epinephrine medical

"intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting"

Epinephrine, also known as adrenaline, is a fast-acting hormone and medication used to stimulate the heart, open airways and tighten blood vessels during life-threatening emergencies like severe allergic reactions, asthma attacks and cardiac arrest. Investors care because its clinical use and demand drive sales of drug products and delivery devices, influence regulatory approvals and supply chains, and can quickly affect revenue and stock value when shortages, new formulations or policy changes occur.

anaphylaxis medical

"delivery option for the treatment of anaphylaxis, where seconds truly matter."

Anaphylaxis is a sudden, severe allergic reaction in which the body's defense system overreacts to a trigger (like a drug, food, or insect sting), causing widespread symptoms such as difficulty breathing, low blood pressure, and shock; it can be life‑threatening without prompt treatment. Investors care because anaphylaxis risks can affect a drug or product's safety profile, regulatory approval, liability exposure and market acceptance—similar to a sprinkler system going off and damaging the whole house rather than just one room.

nasal cavity medical

"Nasal powder has significantly higher deposition in the nasal cavity in comparison to liquid"

The nasal cavity is the hollow space inside the nose that warms, filters and directs air to the lungs and houses tissues involved in smell and immune defense; think of it as a built‑in air conditioning and security checkpoint for the respiratory system. Investors care because many drugs, vaccines and diagnostic tests target or are affected by this area (for delivery, absorption or local disease), and its condition influences regulatory risk, market size and clinical outcomes.

freeze-thaw cycles technical

"FMXIN002 Epinephrine Intranasal Powder Spray is Stable Throughout 3 Freeze-Thaw Cycles"

Freeze-thaw cycles are repeated processes of freezing a product or biological material and then thawing it back to liquid; each cycle can damage delicate molecules or packaging like repeatedly refreezing and reheating leftovers. For investors, they matter because such damage can reduce drug potency, shorten shelf life, increase waste, trigger regulatory problems or recalls, and raise manufacturing and distribution costs that hurt a company’s revenue and reputation.

AI-generated analysis. Not financial advice.

TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company’s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2.

“We are excited to share data highlighting NS002’s potential for superior epinephrine absorption and robust formulation stability,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “Designed as a needle-free intranasal powder, NS002 aims to deliver epinephrine more rapidly in emergency situations, and the data being presented underscore the potential advantages of the powder technology. We believe NS002 represents a unique and potentially superior differentiated epinephrine delivery option for the treatment of anaphylaxis, where seconds truly matter.”

Presentation details:

Nasal epinephrine spray for anaphylaxis: which is better - powder or liquid? Nasal powder has significantly higher deposition in the nasal cavity in comparison to liquid nasal spray which could lead to enhanced blood absorption	Title:
Poster presentation	Format:
Tair Lapidot, PhD, VP R&D and Clinical Development, Nasus Pharma	Corresponding author:
Anaphylaxis and Venom Allergy	Session:
March 1, 2026, at 9:45-10:45 AM	Session date and time:
592	Poster ID:
Convention Center, Level 2, Hall E	Location:

###

FMXIN002 Epinephrine Intranasal Powder Spray is Stable Throughout 3 Freeze-Thaw Cycles	Title:
Poster presentation	Format:
Tair Lapidot, PhD, VP R&D and Clinical Development, Nasus Pharma	Corresponding author:
Anaphylaxis and Venom Allergy	Session:
March 1, 2026, at 9:45-10:45 AM	Session date and time:
593	Poster ID:
Convention Center, Level 2, Hall E	Location:

About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus’ proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the potential of NS002 for superior epinephrine absorption; its aim to deliver epinephrine more rapidly in emergency situations; and the belief that NS002 represents a unique and potentially superior differentiated epinephrine delivery option for the treatment of anaphylaxis. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s prospectus dated August 12, 2025 filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

FAQ

What data will Nasus Pharma (NSRX) present on NS002 at AAAAI 2026?

Nasus Pharma will present posters showing higher nasal deposition for NS002 powder and formulation stability across freeze–thaw cycles. According to the company, posters on March 1, 2026 at 9:45–10:45 AM detail deposition benefits and three-cycle stability findings.

When and where will Nasus Pharma (NSRX) present NS002 posters at AAAAI 2026?

The NS002 posters are scheduled for March 1, 2026, 9:45–10:45 AM at the convention center, Level 2 Hall E. According to the company, both poster presentations are in the Anaphylaxis and Venom Allergy session.

What does the nasal deposition result mean for NS002 (NSRX) in treating anaphylaxis?

Higher nasal deposition suggests better local delivery that could lead to enhanced epinephrine absorption. According to the company, increased deposition versus liquid spray may support faster systemic uptake in emergency anaphylaxis situations.

What stability findings will Nasus Pharma (NSRX) report for its intranasal epinephrine powder?

The company will report that the epinephrine powder remained stable through three freeze–thaw cycles. According to the company, this stability data supports robustness of the powder formulation under varying storage conditions.

Who are the presenters for Nasus Pharma (NSRX) NS002 posters at AAAAI 2026?

Presenters include Tair Lapidot, PhD, VP R&D and Clinical Development, as corresponding author. According to the company, the posters are listed under poster IDs 592 and 593 in the Anaphylaxis and Venom Allergy session on March 1.